TNYA
Tenaya Therapeutics IncKey Statistics
About Tenaya Therapeutics Inc
Tenaya Therapeutics Inc. is a clinical-stage biotechnology innovator committed to revolutionizing heart disease treatment through its proprietary engineered heart cell platform. The company is addressing significant unmet needs in cardiovascular medicine by developing advanced gene therapies and regenerative solutions, with a robust pipeline of candidates targeting various heart disease indications. Tenaya's scientific rigor and focus on patient outcomes position it as a compelling investment opportunity in the biopharmaceutical sector, appealing to institutional investors seeking to support advancements in cardiac care. Its strategic initiatives underscore the potential for impactful contributions to the evolving landscape of cardiovascular therapies.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-84.89M |
| Operating Margin | 0.00% |
| Return on Equity | -83.80% |
| Return on Assets | -43.70% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.57 |
| Price-to-Book | 1.23 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -0.67 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $217.00M |
| Float | $166.77M |
| % Insiders | 0.54% |
| % Institutions | 50.23% |
Historical Volatility
Volatility is currently contracting